General Inception

Enable Medicine is a biotechnology company based in Menlo Park, California, founded in 2019 by Aaron Mayer and Sunil Bodapati. The company specializes in spatial biology data, offering a cloud-based platform that facilitates the generation, management, and analysis of various biological image formats. Enable Medicine's platform provides end-to-end services, including custom panel development and advanced imaging technology, which support researchers, drug developers, and physicians in creating detailed cellular maps. This comprehensive approach enables users to extract valuable insights from diverse sample types, thereby accelerating the drug discovery process and reducing associated costs.

Tavira Therapeutics develops an advanced platform that enhances gene delivery of AAV (adeno-associated virus). The company's approach is to equip AAV vectors with specific molecules that allow for more targeted and safer gene therapies, representing a significant advancement in the field. Founded as a spin-off from KU Leuven and Trellis, Tavira is leveraging groundbreaking research to develop modular AAV capsid technologies to improve gene therapy treatments.

Pharmacelera is a biotechnology company focused on revolutionizing drug discovery through advanced computational methods. By employing accurate quantum-mechanics algorithms, machine learning, and high-performance computing, Pharmacelera explores vast and largely uncharted chemical spaces to identify molecular candidates with increased potential for drug development. Its platform utilizes a three-dimensional representation of molecules that captures crucial interactions such as electrostatic, steric, and hydrophobic fields, derived from semi-empirical quantum-mechanics calculations. This innovative approach has been backed by over 25 years of research at the University of Barcelona and has been validated through scientific publications and user benchmarking studies. Pharmacelera aims to enhance the efficiency and effectiveness of drug discovery projects for bioinformaticians and medicinal chemists.

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

Sestina Bio, LLC is a biotechnology company founded in 2020 and based in Delaware. The company focuses on developing a synthetic biology platform that engineers yeast and bacteria to produce chemicals and pharmaceuticals. Sestina Bio integrates innovative advances in synthetic biology, data sciences, and bio-analytical systems to create solutions addressing significant global challenges, such as sustainable food production, clothing, and health for an expanding population. Their offerings include tools for genome editing, single-cell biology, and machine learning, which enhance researchers' capabilities to engineer and exploit new biological functions.

Switchback Systems is an early-stage startup founded in 2019 by Mary Noe, specializing in the development of a scalable DNA synthesis platform. The company aims to significantly reduce the time, cost, and waste associated with nucleic acid applications. Its innovative platform utilizes advanced technologies to facilitate the use of cell structure as a data storage medium. By offering a benchtop DNA printer, Switchback Systems provides the healthcare industry with on-demand biological discovery capabilities, catering to the needs of laboratories and enhancing their research efficiency.